NasdaqGM:AUPHBiotechs
Aurinia Pharmaceuticals (AUPH) Q1 EPS Of US$0.26 Tests Bullish Margin Narratives
Aurinia Pharmaceuticals (AUPH) opened Q1 2026 with total revenue of US$77.7 million, basic EPS of US$0.26, and trailing 12 month EPS of US$2.25, following a year in which earnings grew very sharply and the company moved to a 100% net margin. The company has seen quarterly revenue move from US$59.9 million in Q4 2024 to US$62.5 million in Q1 2025 and then to US$77.7 million in Q1 2026, while basic EPS has shifted over the same period from US$0.01 to US$0.17 and then to US$0.26. This has set up...